Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $13.78.

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a research note on Friday, March 8th. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Finally, Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their target price for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd.

Insider Activity at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the transaction, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at $132,062.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Richard D. Francis sold 74,530 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the sale, the chief executive officer now directly owns 87,125 shares of the company’s stock, valued at approximately $1,145,693.75. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Amir Weiss sold 31,766 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 390,738 shares of company stock worth $5,132,766. Company insiders own 0.62% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 30.3% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 206,162 shares of the company’s stock worth $2,909,000 after purchasing an additional 47,954 shares during the period. Atlas Capital Advisors LLC raised its stake in Teva Pharmaceutical Industries by 3,427.6% during the 1st quarter. Atlas Capital Advisors LLC now owns 43,742 shares of the company’s stock worth $617,000 after acquiring an additional 42,502 shares in the last quarter. Range Financial Group LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter worth $797,000. Park Avenue Securities LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at $248,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $82,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.8 %

NYSE TEVA opened at $13.19 on Friday. The stock has a market capitalization of $14.79 billion, a price-to-earnings ratio of -28.06, a PEG ratio of 1.59 and a beta of 1.05. Teva Pharmaceutical Industries has a 52 week low of $7.09 and a 52 week high of $14.47. The stock’s 50 day moving average price is $13.45 and its two-hundred day moving average price is $11.21. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. The firm had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. As a group, analysts anticipate that Teva Pharmaceutical Industries will post 2.28 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.